Manus
Americas
Cambridge
,
United States
Scaleup
FOUNDED
2011
HEADCOUNT
101-500
FUNDING
Series B
Keywords:
precision_fermentation, metabolic_engineering, flavors, fragrances, sweeteners, vitamins, therapeutics
BUSINESS
Manus (formerly Manus Bio / Manus Biosynthesis), founded in 2011 and based in Waltham, MA, was spun out of Greg Stephanopoulos's metabolic engineering lab at MIT and produces complex natural products (flavors, fragrances, food ingredients, sweeteners, vitamins, pharmaceuticals, agricultural chemicals) via engineered microbial fermentation. The company operates an R&D site in Boston and a large precision fermentation BioFacility in Augusta, Georgia, which is undergoing expansion. In April 2025, Manus merged with Inscripta, the Colorado-based CRISPR strain engineering company, adding the GenoScaler platform and MAD7 nuclease licensing program to its capabilities. Commercial partnerships include a joint sweetener brand (Yume) with Tate & Lyle launched in late 2025
BIOTECH INVOLVEMENT
Core; metabolic-engineering company (MIT spin-out, 2011) producing complex natural products (flavors, fragrances, sweeteners, vitamins, pharma intermediates) via precision fermentation.
TECHNOLOGY PLATFORM
precision fermentation; metabolic engineering; microbial cell factories
PRIMARY PRODUCTS
Yume stevia sweetener; Nootkatone; Valencene